Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 19515 | 437 | 34.5 | 75% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | BREAST CARCINOMA CELL LINE | Author keyword | 1 | 40% | 0% | 2 |
| 2 | BIOTINYLATED EPIDERMAL GROWTH FACTOR | Author keyword | 1 | 50% | 0% | 1 |
| 3 | BREAST CANCER BIOPSIES | Author keyword | 1 | 50% | 0% | 1 |
| 4 | ENDOMETRIAL ADENOMATOSIS | Author keyword | 1 | 50% | 0% | 1 |
| 5 | EPIDERMAL GROWTH FACTOR EGF RECEPTOR EGFR | Author keyword | 1 | 50% | 0% | 1 |
| 6 | GENE DOSAGE PCR | Author keyword | 1 | 50% | 0% | 1 |
| 7 | IMMUNOCYTOCHEMICAL ASSAYS | Author keyword | 1 | 50% | 0% | 1 |
| 8 | INTERACTING PATHWAYS | Author keyword | 1 | 50% | 0% | 1 |
| 9 | INTRON DIFFERENTIAL RNA PCR | Author keyword | 1 | 50% | 0% | 1 |
| 10 | KASHAN ANAT | Address | 1 | 50% | 0% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | HUMAN MAMMARY CARCINOMAS | 5 | 54% | 2% | 7 |
| 2 | EGF R | 5 | 23% | 4% | 18 |
| 3 | ACID ETHANOL EXTRACTION | 1 | 50% | 0% | 1 |
| 4 | FACTOR EGF R | 1 | 50% | 0% | 1 |
| 5 | FACTOR I IGF 1 R | 1 | 50% | 0% | 1 |
| 6 | LINE HMT 3522 | 1 | 50% | 0% | 1 |
| 7 | SOMATOSTATIN SS R | 1 | 50% | 0% | 1 |
| 8 | FACTOR RECEPTOR STATUS | 1 | 22% | 0% | 2 |
| 9 | EGF LIKE FACTORS | 0 | 14% | 1% | 3 |
| 10 | TUMOR BIOPSIES | 0 | 13% | 1% | 3 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| THE CLINICAL-SIGNIFICANCE OF EPIDERMAL GROWTH-FACTOR RECEPTOR (EGF-R) IN HUMAN BREAST-CANCER - A REVIEW ON 5232 PATIENTS | 1992 | 479 | 80 | 63% |
| Clinical value of epidermal growth factor receptor expression in primary breast cancer | 2005 | 24 | 14 | 50% |
| GROWTH-FACTOR SYNTHESIS AND HUMAN BREAST-CANCER PROGRESSION | 1995 | 115 | 101 | 15% |
| The relationship between prognostic and predictive factors in the management of breast cancer | 1998 | 97 | 224 | 12% |
| Epidermal growth factor receptors in breast cancer: from experiment to clinical practice | 1998 | 0 | 64 | 58% |
| EGF RECEPTOR EXPRESSION, REGULATION, AND FUNCTION IN BREAST-CANCER | 1994 | 91 | 109 | 17% |
| CELL BIOLOGICAL FACTORS ASSOCIATED WITH THE RESPONSE OF BREAST-CANCER TO SYSTEMIC TREATMENT | 1993 | 46 | 75 | 15% |
| Protein tyrosine kinases and cancer | 1997 | 95 | 377 | 8% |
| EPIDERMAL GROWTH-FACTOR IN BREAST-CANCER | 1990 | 11 | 85 | 40% |
| THE MONOCLONAL-ANTIBODY PROGRAM OF THE CUBAN-INSTITUTE-OF-ONCOLOGY-AND-RADIOBIOLOGY | 1990 | 0 | 11 | 36% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | KASHAN ANAT | 1 | 50% | 0.2% | 1 |
| 2 | NN BLOKIN ONCOL | 1 | 50% | 0.2% | 1 |
| 3 | PATHOL ANAT HUMAN TUMORS | 1 | 50% | 0.2% | 1 |
| 4 | SEMIOT SURG | 1 | 50% | 0.2% | 1 |
| 5 | UNITAT REC TRANSLAC TUMORS SOLIDS | 1 | 50% | 0.2% | 1 |
| 6 | BREAST GYNECOL | 0 | 25% | 0.2% | 1 |
| 7 | ICRF MOL ONCOL | 0 | 25% | 0.2% | 1 |
| 8 | OBSTET GYNECOL LARGO GEMELLI 8 | 0 | 20% | 0.2% | 1 |
| 9 | UNIT BIOINFORMAT BIOSTAT SIGNALLING | 0 | 20% | 0.2% | 1 |
| 10 | GLENFIELD HOSP NHS TRUST | 0 | 17% | 0.2% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000261558 | TRANSFORMING GROWTH FACTOR ALPHA//TGF ALPHA//HTGF ALPHA |
| 2 | 0.0000198456 | MED OBSTET GYNECOL1150 FUKUSHIMA//MED RALPH L SMITH PHYSIOL//ADV TECHNOL PLICAT ILTEK |
| 3 | 0.0000191564 | IMMUNOGENE//MED MOLEC BIOL SHINJUKU KU//ERBB PROTEINS |
| 4 | 0.0000182526 | C ERBB 2//HER 2 NEU//P185 |
| 5 | 0.0000179701 | EGF POLYMORPHISM//GEFITINIB THERAPY//INTRON 1 POLYMORPHISM |
| 6 | 0.0000138480 | NIMOTUZUMAB//H R3//CETUXIMAB |
| 7 | 0.0000115641 | AEBS//ANTIESTROGEN BINDING SITES//ANALOG II |
| 8 | 0.0000103517 | ER ICA//IMMUNOCYTOCHEMICAL ASSAY//PROGESTERONE RECEPTORS |
| 9 | 0.0000096355 | BENIGN MASTOPATHIES//PRIMARY HUMAN BREAST CANCER//BOVINE MAMMARY CELLS |
| 10 | 0.0000091509 | ESTROGEN RECEPTOR VARIANTS//JC HEUSON CANCEROL MAMMAIRE//SERV HISTOL CYTOL EXPT |